Background. Infusion of donor bone marrow cells induces tolerance in allograft models. CD34 + stem cells present in human bone marrow could be endowed with tolerogenic properties. Methods. CD34 + stem cells were isolated from bone marrow extracted from vertebral bodies of cadaveric donors. Donor CD34 + cells (0.6-3.7 x 10 6jkg) were infused during surgery in 10 kidney transplant recipients receiving OKT3 as induction therapy. Chimerism was investigated using nested PCR for donor-specific HLA alleles. Results. The infusion of CD34 + stem cells was perfectly tolerated. Five patients remained free of acute rejection at follow-up, 47-325 days post-operatively. The five other patients underwent a single episode of corticosensitive acute rejection. Long-term chimerism was not induced in the seven patients investigated for the persistence of donor DNA. Conclusions. Infusion of donor CD34 + stem cells in kidney transplantation is safe. The clinical usefulness of the procedure remains to be established.
longed liver allograft survival as a consequence of this treatment was recently provided [6] .
The bone marrow cells responsible for the induction of tolerance in experimental models were defined as veto cells [7, 8] . Although they were found to express CD8 and to secrete transforming growth factor-beta [8] , the precise phenotype of veto cells present in bone marrow has not yet been fully characterized. Data obtained recently by Rondelli et al. suggested that a subset of CD34 + bone marrow stem cells expressing HLA-DR but lacking costimulatory molecules might be endowed with tolerogenic properties [9] . Interestingly, donor-derived CD34 + cells were found to persist for a prolonged period in the bone marrow of kidney transplant recipients having received donor bone marrow cells [10] . On this basis, we reasoned that infusion of CD34 + stem cells purified from donor bone marrow might promote allograft acceptance in kidney transplant recipients. An additional advantage of this strategy, compared with unseparated bone marrow cells, would be to reduce the risk of inducing graft-versus-host reaction because of donor T-cell depletion. As a first step, we undertook the present study to determine the feasibility of the purification of CD34 + stem cells from cadaver vertebral bodies and the safety of the infusion of such cell suspensions in kidney transplant recipients.
For isolation of cadaver donor CD34 + cells, bone marrow was obtained from cancellous bone extracted from 5 to 7 vertebral bodies (thoracic or lumbar) obtained at the end of the organ retrieval procedure, according to previously published protocols [5, 11] . The medium used for bone marrow processing consisted of Xvivo 10 (BioWhittaker, Walkersville, MA, USA) supplemented with 10 Ujml heparin (Leo Pharmaceutical Products, Ballerup, Denmark) and 80 ug/ml gentamicin (Schering-Plough, Hcist-op-denBerg, Belgium). Bone chips were purged by gentle agitation, and bone marrow cells passed through stacked sieves were pooled into six blood bags (Baxter, Deerfield, II, USA) to which Xvivo 10 medium containing 10 Ujml recombinant human DNAse © 1998 European Renal Association-European Dialysis and Transplant Association CD34 + stem cells in kidney transplantation (Pulmozyme'", Hoffman-La Roche, GrenpachWyhlen, Switzerland) was added to reach a final volume of 500 ml. The bags were then centrifuged at 150 g for 15 min at room temperature. This procedure was repeated four times before resuspension of the cells in sterile PBS containing 5% human serum albumin (Belgian Red Cross, Brussels, Belgium) and 10 Ujml DNAse. In preliminary experiments, the addition of DNAse was found to be essential to avoid the formation of clumps which prevented further cell manipulations. CD34 + cell enrichment was performed with the CEPRATE SC stem cell concentration system (Cellpro, Bothell, WA, USA), according to manufacturer's protocol. Briefly, bone marrow cells were incubated with biotinylated anti-CD34 monoclonal antibody and then passed through the Ceprate SC avidinimmunoaffinity column. Finally, bound CD34 + cells were released by gentle agitation and kept at 4DC in PBS containing 5% human albumin and 1 Ujml DNAse until infusion. The complete procedure including bone harvesting took ""10 h. The cell numbers and the percentages of CD34 + and CD3 + cells before and after passage on the Cellpro device are given in Table  1 . The yield of CD34 + cell recovery ranged between 15 and 33% (mean: 20.5%), which represents about half the percentages obtained from CD34 + cell selec-35 tion of cytapheresis performed after peripheral blood stem cell mobilization (mean of 27 procedures in our institution: 41%). The CD34 + cell enrichment (14-to 54-fold increase in the percentage CD34 + cells) was associated with a 2 to 3 log reduction in the absolute numbers of CD3 + cells, which is similar to the degree of T-cell depletion obtained using cytapheresis material. Cell viability assessed by trypan blue exclusion immediately before infusion was above 90% in each case.
After approval by the local ethical committee and written informed consent, 10 recipients of a first cadaver kidney allograft with a panel of reactive antibodies below 80% were elected to receive infusion of donor CD34 + stem cells during transplantation surgery. The immunosuppressive regimen consisted of OKT3 5mgjday from day 0 to day 13 post-transplantation, together with low dose prednisolone (0.3 rug/kg/day, tapered to 0.17 rug/kg/day by month 4) and azathioprine (2 rug/kg/day, tapered to 1 mgjkgjday by day 14). An iv bolus of 500 mg methylprednisolone was given 2 h before the first injection of OKT3 to mitigate OKT3-induced first reactions, as previously described [12] . Cyclosporin A (6 rug/kg/day) was started between day 6 and day 11, depending on the renal function. For the establishment of this protocol, we reasoned that the cytokines released after the first injection of OKT3 could promote engraftment of the donor cells. The infusion of CD34 + cells (0.6-3.7 x 10 6 cells/kg, see Table 2 ) was perfectly tolerated in every patient. No signs of acute or chronic graft-versus-host reaction were observed and opportunistic infections were not encountered. Data given in Table 2 summarize the outcome of the 10 patients treated in terms of acute rejection episodes and renal function. Five out of 10 patients were free of acute rejection episode at followup. In the five patients who experienced acute rejection, the rejection process was confirmed by graft biopsy and rapidly reversed by increasing corticosteroid dosage, so that all 10 grafts were functioning at follow-up.
Chimerism was assessed in peripheral blood in seven patients by nested PCR for donor-specific HLA-B or HLA-DR allele, as previously described [13, 14] . In 3 patients, chimerism was undetectable at each time point investigated (1 month, 2 months postoperatively). In four patients, chimerism was present at 1 week; two of them were still chimeric at 1 month but not at 2 months. Because a recent study suggested that donor cells might home preferentially in bone marrow, iliac crest bone marrow aspiration was performed in three patients between 6 months and 1 year post-transplantation. Chimerism was undectable in all three samples. The lack of persistent chimerism following donor CD34 + cell infusion might be due to the administration of an insufficient number of cells. Indeed, both in experimental models and in clinical trials, long-term engraftment of allogenic cells in the absence of myeloablation seems to depend on the administration of a high ('mega') dose of stem cells [6, 15] which is at least ten times higher than the dose used in the present study. The timing of CD34 + cells infusion could also be critical, as the facilitating effect of bone marrow infusion in liver allograft recipients was only observed when it was delayed until day 5 post-transplantation [6] , in agreement with experimental data [16] . The period between CD34 + cell collection and infusion could be exploited to expand stem cells in vitro using established protocols [17] .
We conclude that infusion of donor CD34 + cell infusion is a feasible and safe procedure in cadaver kidney transplantation and that additional efforts should be made to determine the optimal conditions of such protocols in terms of cell dose and timing of administration.
